Title |
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
|
---|---|
Published in |
Cochrane database of systematic reviews, March 2015
|
DOI | 10.1002/14651858.cd009444.pub3 |
Pubmed ID | |
Authors |
Ying Li, Shan Hai, Yan Zhou, Bi Rong Dong |
Abstract |
Rarer dementias include Huntington's disease (HD), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), frontotemporal dementia (FTD), dementia in multiple sclerosis (MS) and progressive supranuclear palsy (PSP). Cholinesterase inhibitors, including donepezil, galantamine and rivastigmine, are considered to be the first-line medicines for Alzheimer's disease and some other dementias, such as dementia in Parkinson's disease. Cholinesterase inhibitors are hypothesised to work by inhibiting the enzyme acetylcholinesterase (AChE) which breaks down the neurotransmitter acetylcholine. Cholinesterase inhibitors may also lead to clinical improvement for rarer dementias associated with neurological conditions. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Bosnia and Herzegovina | 1 | 20% |
France | 1 | 20% |
Belgium | 1 | 20% |
United States | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Czechia | 1 | <1% |
Germany | 1 | <1% |
Unknown | 335 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 45 | 13% |
Student > Ph. D. Student | 42 | 12% |
Student > Master | 42 | 12% |
Researcher | 35 | 10% |
Student > Postgraduate | 20 | 6% |
Other | 51 | 15% |
Unknown | 104 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 91 | 27% |
Psychology | 36 | 11% |
Nursing and Health Professions | 26 | 8% |
Neuroscience | 23 | 7% |
Biochemistry, Genetics and Molecular Biology | 11 | 3% |
Other | 37 | 11% |
Unknown | 115 | 34% |